162 related articles for article (PubMed ID: 29601261)
1. EPAS1 Mutations and Paragangliomas in Cyanotic Congenital Heart Disease.
Vaidya A; Flores SK; Cheng ZM; Nicolas M; Deng Y; Opotowsky AR; Lourenço DM; Barletta JA; Rana HQ; Pereira MA; Toledo RA; Dahia PLM
N Engl J Med; 2018 Mar; 378(13):1259-1261. PubMed ID: 29601261
[No Abstract] [Full Text] [Related]
2. Identification of Novel Mutations and Expressions of
Islam F; Pillai S; Gopalan V; Lam AK
Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33114456
[TBL] [Abstract][Full Text] [Related]
3. Chiari Malformation Type 1 in
Rosenblum JS; Maggio D; Pang Y; Nazari MA; Gonzales MK; Lechan RM; Smirniotopoulos JG; Zhuang Z; Pacak K; Heiss JD
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185588
[TBL] [Abstract][Full Text] [Related]
4. Paraganglioma and cyanotic congenital heart disease: The role of tisular hipoxia.
Oleaga-Alday A; Goñi-Goicoechea F; Calles-Romero L; Pérez de Ciriza-Cordeu M; Paja-Fano M
Endocrinol Nutr; 2015 Oct; 62(8):413-4. PubMed ID: 26112697
[No Abstract] [Full Text] [Related]
5. Paraganglioma in Cyanotic Congenital Heart Disease.
Shaw T; Parrish D; Simpson S; Morris M
Am Surg; 2021 Jan; 87(1):103-104. PubMed ID: 32833502
[No Abstract] [Full Text] [Related]
6. Mutations in EPAS1 in congenital heart disease in Tibetans.
Pan H; Chen Q; Qi S; Li T; Liu B; Liu S; Ma X; Wang B
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30487161
[No Abstract] [Full Text] [Related]
7. Pheochromocytoma and paraganglioma in cyanotic congenital heart disease.
Opotowsky AR; Moko LE; Ginns J; Rosenbaum M; Greutmann M; Aboulhosn J; Hageman A; Kim Y; Deng LX; Grewal J; Zaidi AN; Almansoori G; Oechslin E; Earing M; Landzberg MJ; Singh MN; Wu F; Vaidya A
J Clin Endocrinol Metab; 2015 Apr; 100(4):1325-34. PubMed ID: 25581599
[TBL] [Abstract][Full Text] [Related]
8. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis.
Comino-Méndez I; de Cubas AA; Bernal C; Álvarez-Escolá C; Sánchez-Malo C; Ramírez-Tortosa CL; Pedrinaci S; Rapizzi E; Ercolino T; Bernini G; Bacca A; Letón R; Pita G; Alonso MR; Leandro-García LJ; Gómez-Graña A; Inglada-Pérez L; Mancikova V; Rodríguez-Antona C; Mannelli M; Robledo M; Cascón A
Hum Mol Genet; 2013 Jun; 22(11):2169-76. PubMed ID: 23418310
[TBL] [Abstract][Full Text] [Related]
9. Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.
Welander J; Andreasson A; Brauckhoff M; Bäckdahl M; Larsson C; Gimm O; Söderkvist P
Endocr Relat Cancer; 2014 Jun; 21(3):495-504. PubMed ID: 24741025
[TBL] [Abstract][Full Text] [Related]
10. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.
Toledo RA; Qin Y; Srikantan S; Morales NP; Li Q; Deng Y; Kim SW; Pereira MA; Toledo SP; Su X; Aguiar RC; Dahia PL
Endocr Relat Cancer; 2013 Jun; 20(3):349-59. PubMed ID: 23533246
[TBL] [Abstract][Full Text] [Related]
11. Developmental vascular malformations in EPAS1 gain-of-function syndrome.
Rosenblum JS; Wang H; Dmitriev PM; Cappadona AJ; Mastorakos P; Xu C; Jha A; Edwards N; Donahue DR; Munasinghe J; Nazari MA; Knutsen RH; Rosenblum BR; Smirniotopoulos JG; Pappo A; Spetzler RF; Vortmeyer A; Gilbert MR; McGavern DB; Chew E; Kozel BA; Heiss JD; Zhuang Z; Pacak K
JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33497361
[TBL] [Abstract][Full Text] [Related]
12. HIF2 and endocrine neoplasia: an evolving story.
Maher ER
Endocr Relat Cancer; 2013 Jun; 20(3):C5-7. PubMed ID: 23653463
[TBL] [Abstract][Full Text] [Related]
13. Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome.
Dmitriev PM; Wang H; Rosenblum JS; Prodanov T; Cui J; Pappo AS; Gilbert MR; Lutty GA; Chan CC; Chew EY; Pacak K; Zhuang Z
JAMA Ophthalmol; 2020 Feb; 138(2):148-155. PubMed ID: 31876943
[TBL] [Abstract][Full Text] [Related]
14. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma.
Lorenzo FR; Yang C; Ng Tang Fui M; Vankayalapati H; Zhuang Z; Huynh T; Grossmann M; Pacak K; Prchal JT
J Mol Med (Berl); 2013 Apr; 91(4):507-12. PubMed ID: 23090011
[TBL] [Abstract][Full Text] [Related]
15. HIF2A gain-of-function mutations detected in duodenal gangliocytic paraganglioma.
Zhuang Z; Yang C; Ryska A; Ji Y; Hou Y; Graybill SD; Bullova P; Lubensky IA; Klöppel G; Pacak K
Endocr Relat Cancer; 2016 May; 23(5):L13-6. PubMed ID: 27130043
[No Abstract] [Full Text] [Related]
16. Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome.
Kamihara J; Hamilton KV; Pollard JA; Clinton CM; Madden JA; Lin J; Imamovic A; Wall CB; Wassner AJ; Weil BR; Heeney MM; Vargas SO; Kaelin WG; Janeway KA; Perini RF; Zojwalla NJ; Voss SD; DuBois SG
N Engl J Med; 2021 Nov; 385(22):2059-2065. PubMed ID: 34818480
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster.
Fliedner SM; Shankavaram U; Marzouca G; Elkahloun A; Jochmanova I; Daerr R; Linehan WM; Timmers H; Tischler AS; Papaspyrou K; Brieger J; de Krijger R; Breza J; Eisenhofer G; Zhuang Z; Lehnert H; Pacak K
Neoplasia; 2016 Sep; 18(9):567-76. PubMed ID: 27659016
[TBL] [Abstract][Full Text] [Related]
18. Antiphospholipid syndrome in patients with cyanotic congenital heart disease.
Martínez-Lavín M; Fonseca C; Amigo MC; Nava A; Reyes PA; Ruiz-Argüelles A
Clin Exp Rheumatol; 1995; 13(4):489-91. PubMed ID: 7586782
[TBL] [Abstract][Full Text] [Related]
19. Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome.
Buffet A; Smati S; Mansuy L; Ménara M; Lebras M; Heymann MF; Simian C; Favier J; Murat A; Cariou B; Gimenez-Roqueplo AP
J Clin Endocrinol Metab; 2014 Feb; 99(2):E369-73. PubMed ID: 24276449
[TBL] [Abstract][Full Text] [Related]
20. Long-Standing Cyanosis in Congenital Heart Disease Does not Cause Diffuse Myocardial Fibrosis.
Kharabish A; Meierhofer C; Hadamitzky M; Nadjiri J; Martinoff S; Ewert P; Stern H
Pediatr Cardiol; 2018 Jan; 39(1):105-110. PubMed ID: 28948316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
